TERLIPRESSIN'S EFFECT ON HEPATORENAL DISEASE: AN OBSERVATIONAL, DESCRIPTIVE, CROSS-SECTIONAL STUDY
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 3, Pages 1557-1571
AbstractWith the help of clinical and biochemical tests, we will evaluate the relative benefits of Terlipressin in combination with albumin against albumin alone for treating hepatorenal syndrome. The eighty patients were divided evenly. Albumin was the sole treatment for Group 1, whereas Terlipressin was added to the mix for Group 2. The information was analysed with IBM SPSS 20. The tables were made using a combination of a frequency distribution and a cross-tabulation. The data is presented with a mean, standard deviation, and median (minimum–maximum). Student's t and Mann–Whitney tests were employed to compare continuous variables. “Analyzing categorical data with the Pearson Chi square and Fisher's exact test Less than 0.05 was considered statistically significant. The non-significant p value of 0.79 reveals no difference in etiology distribution between treatments. With the exception of SGOT (p = 0.002), which was lower in the Terlipressin + albumin treatment group (61.89± 47.83) than albumin alone, total bilirubin, SGPT, INR, and serum albumin were all the same in both groups (96.80±109.30). Terlipressin and albumin reduced serum creatinine. Serum creatinine dropped 50.14 percent (1.73 ± 1.49) from day 1 (3.47 ±1.68) to day 5. Albumin patients fell 9.33%. Serum creatinine decreased in the albumin group (p = 0.237)”. Every measure, with the exception of SGOT, which was much lower in the Terlipressin plus albumin treatment group and may indicate a better safety profile, was equivalent in both groups, including total bilirubin, SGPT, INR, and serum albumin. Blood creatinine levels upon admission and on day five revealed that patients who took Terlipressin with albumin fared better in terms of their health and biochemistry.
- Article View: 6
- PDF Download: 6